Lippman Evan bought TEVA
March 4, 2026 · Form 4 insider transaction
Lippman Evan bought 27,347 shares of Teva Pharmaceutical Industries Limited at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 2 days after the transaction.
Footnotes
Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.; Restricted share units were granted on March 4, 2026, with 6,836 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 6,839 vesting on March 4, 2030.; The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.